To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique
Introduction: Despite the growing body of evidence supporting the efficacy of subconjunctival bevacizumab injection, questions remain regarding its comparative effectiveness against conventional surgical techniques. Aims and Objectives: The aim of the study was to evaluate the efficacy of subconjunc...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of Clinical Ophthalmology and Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jcor.jcor_24_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087286055960576 |
|---|---|
| author | Nusrat Shaheen Abdul Gafoor Ahmed Sheikh Sajjad Wasim Rashid Aamir Rashid |
| author_facet | Nusrat Shaheen Abdul Gafoor Ahmed Sheikh Sajjad Wasim Rashid Aamir Rashid |
| author_sort | Nusrat Shaheen |
| collection | DOAJ |
| description | Introduction:
Despite the growing body of evidence supporting the efficacy of subconjunctival bevacizumab injection, questions remain regarding its comparative effectiveness against conventional surgical techniques.
Aims and Objectives:
The aim of the study was to evaluate the efficacy of subconjunctival bevacizumab injection before pterygium surgery with bare sclera technique in preventing postoperative reoccurrence.
Materials and Methods:
The present study was a comparative, randomized prospective study. Patients included were divided into two groups of 50 patients each. Patients in Group A received bevacizumab 2.5 mg/0.1 ml, and patients in Group B received subconjunctival balanced salt solution 0.1 ml. The primary outcome was recurrence of pterygium at 6 weeks and 6 months.
Results:
The total number of patients was 100. The mean age was 36.9 ± 8.67 years. The left eye was involved in more, i.e., 61 than the right eye 39. Majority of patients in Group A, i.e., 30 (60%) and in Group B 31 (62%) had Grade 2 pterygium, followed by Grade 3 pterygium in 17 (34%) in Group A and 15 (30%) in Group B. The recurrence rate at 6 weeks was 6% (3 patients) in Group A while it was 22% (11 patients) in Group B (P = 0.021). The recurrence rate at 6 months was 8% (4 patients) in Group A while it was 26% (13 patients) in Group B (P = 0.017).
Conclusion:
Subconjunctival injection of bevacizumab before surgery of pterygium is safe and effective in terms of recurrence and the complication rate for primary or recurrent pterygium treatment. |
| format | Article |
| id | doaj-art-f748879e901442a0a4e0cae59e6e1bc8 |
| institution | Kabale University |
| issn | 2320-3897 2320-3900 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Clinical Ophthalmology and Research |
| spelling | doaj-art-f748879e901442a0a4e0cae59e6e1bc82025-02-06T06:38:52ZengWolters Kluwer Medknow PublicationsJournal of Clinical Ophthalmology and Research2320-38972320-39002025-01-01131343810.4103/jcor.jcor_24_24To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera techniqueNusrat ShaheenAbdul Gafoor AhmedSheikh SajjadWasim RashidAamir RashidIntroduction: Despite the growing body of evidence supporting the efficacy of subconjunctival bevacizumab injection, questions remain regarding its comparative effectiveness against conventional surgical techniques. Aims and Objectives: The aim of the study was to evaluate the efficacy of subconjunctival bevacizumab injection before pterygium surgery with bare sclera technique in preventing postoperative reoccurrence. Materials and Methods: The present study was a comparative, randomized prospective study. Patients included were divided into two groups of 50 patients each. Patients in Group A received bevacizumab 2.5 mg/0.1 ml, and patients in Group B received subconjunctival balanced salt solution 0.1 ml. The primary outcome was recurrence of pterygium at 6 weeks and 6 months. Results: The total number of patients was 100. The mean age was 36.9 ± 8.67 years. The left eye was involved in more, i.e., 61 than the right eye 39. Majority of patients in Group A, i.e., 30 (60%) and in Group B 31 (62%) had Grade 2 pterygium, followed by Grade 3 pterygium in 17 (34%) in Group A and 15 (30%) in Group B. The recurrence rate at 6 weeks was 6% (3 patients) in Group A while it was 22% (11 patients) in Group B (P = 0.021). The recurrence rate at 6 months was 8% (4 patients) in Group A while it was 26% (13 patients) in Group B (P = 0.017). Conclusion: Subconjunctival injection of bevacizumab before surgery of pterygium is safe and effective in terms of recurrence and the complication rate for primary or recurrent pterygium treatment.https://journals.lww.com/10.4103/jcor.jcor_24_24bevacizumabpterygiumrecurrence |
| spellingShingle | Nusrat Shaheen Abdul Gafoor Ahmed Sheikh Sajjad Wasim Rashid Aamir Rashid To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique Journal of Clinical Ophthalmology and Research bevacizumab pterygium recurrence |
| title | To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique |
| title_full | To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique |
| title_fullStr | To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique |
| title_full_unstemmed | To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique |
| title_short | To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique |
| title_sort | to evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique |
| topic | bevacizumab pterygium recurrence |
| url | https://journals.lww.com/10.4103/jcor.jcor_24_24 |
| work_keys_str_mv | AT nusratshaheen toevaluatetheefficacyofsubconjunctivalbevacizumabinjectioninvascularpterygiumbeforesurgicalexcisioninpreventingrecurrencecomparingwithbarescleratechnique AT abdulgafoorahmed toevaluatetheefficacyofsubconjunctivalbevacizumabinjectioninvascularpterygiumbeforesurgicalexcisioninpreventingrecurrencecomparingwithbarescleratechnique AT sheikhsajjad toevaluatetheefficacyofsubconjunctivalbevacizumabinjectioninvascularpterygiumbeforesurgicalexcisioninpreventingrecurrencecomparingwithbarescleratechnique AT wasimrashid toevaluatetheefficacyofsubconjunctivalbevacizumabinjectioninvascularpterygiumbeforesurgicalexcisioninpreventingrecurrencecomparingwithbarescleratechnique AT aamirrashid toevaluatetheefficacyofsubconjunctivalbevacizumabinjectioninvascularpterygiumbeforesurgicalexcisioninpreventingrecurrencecomparingwithbarescleratechnique |